Table 1.
Clinico-pathologic characteristics.
Table 2.
Ki67 counts according to tissue categories.
Table 3.
Associations between Ki67 expression and histopathological features.
Figure 1.
Box plots of tumor cell proliferation by Ki67 expression according to breast cancer molecular subgroups in different specimen categories.
Horizontal lines inside the boxes represent the median value; box limits indicate the 25th and 75th percentiles; whiskers extend 1.5 times the interquartile range from the 25th and 75th percentiles.
Figure 2.
Frequency of cases in the Luminal/HER2- subgroup showing high proliferation when applying a Ki67 cutoff-point of 14% to different specimen categories.
WS (n = 415), CNB (n = 125), TMA (n = 350).
Table 4.
Ki67 concordance between WS, CNB and TMA in the luminal subgroup.
Figure 3.
Breast cancer specific survival according to Ki67 expression.
Survival curves (Kaplan-Meier) are shown for Ki67 expression on WS (A); TMA (B) and CNB (C). Cut-off points at the median were applied for all specimen categories. The number of events and total number of patients in each group are shown beside the description of each curve. Numbers at risk are presented below each curve.
Table 5.
Multivariate survival analysis (Cox′ proportional hazards method) using different specimen categories.
Figure 4.
Breast cancer prognosis by molecular subtype.
Survival curves (Kaplan-Meier) for breast carcinomas showing an association between molecular subtype and breast cancer specific survival. The Luminal B subgroup includes Luminal/HER2+ cases. For each category, the number of events is given followed by the number of patients.